Cough variant asthma (CVA) in children can be treated with relative effectiveness and safety with montelukast (Mon) + fluticasone propionate (Flu), according to meta-analysis findings published in BMC Pulmonary Medicine.
Repeated illnesses, hidden onsets, and long courses are common among patients with CVA. Resistance to therapy leads to typical bronchial asthma within a few years in 30% of patients with CVA, thus underlining the urgency of a curative therapy. Investigators therefore sought to assess Mon+Flu vs Flu alone for efficacy and safety in CVA in children.
The investigators conducted a meta-analysis. searching the China Science and Technology Journal, China National Knowledge Infrastructure, WanFang, Embase, and PubMed databases without language restriction until July 2022 for randomized controlled trials (RCTs) focused on Mon+Flu vs Flu in patients with cough variant asthma who were less than 18 years of age. For inclusion, studies needed at least 1 outcome of adverse effects, forced expiratory volume percentage, time to cough remission or disappearance, cough recurrence rate, and treatment efficiency. Cohort, case-control, and cross-sectional studies were excluded.
The investigators included 9 randomized controlled trials (N=926 patients, primarily located in China) in the meta-analysis (Mon+Flu, n=464; Flu alone, n=378; 426 girls). No significant publication bias was found. The literature quality evaluation showed moderate risk bias in evaluation of selection, performance, and detection bias, and overall quality of methodology used in this study was medium.
“
Mon + Flu is effective and safe for the treatment of CVA in children.
The investigators found the total effective rate was significantly improved and cough recurrence reduced with Mon+Flu vs Flu alone (risk ratio [RR] total efficacy rate, 1.30; 95% CI, 1.19-1.43; P <.001) and (RR for reduced cough recurrence, 0.51; 95% CI, 0.31-0.86; P =.01). Heterogeneity among these studies was less than 50%.
Patients using Mon+Flu vs Flu alone experienced significantly improved cough remission and disappearance times. In the random-effects model analysis, the researchers found the weighted mean difference (WMD) in pooled results between Mon+Flu vs Flu alone was -0.33 (P =.05) for symptom score, -2.72 days (P <.001) for cough relief time, and -4.40 days (P <.001) for cough disappearance time.
Pooled results based on the fixed-effect model showed the Mon+Flu group vs Flu alone experienced significantly better forced expiratory volume in 1 second (FEV1) recovery (WMD, 2.65; P =.006). Heterogeneity among these studies was 35%.
Percentage of predicted peak expiratory flow (PEF%) in the Mon+Flu group vs Flu alone improved without statistical significance. Heterogeneity was significant among these studies.
Incidence of adverse effects including headache, dizziness, hoarseness, abdominal pain was not significant compared with control individuals across the included studies and the difference in incidence was not statistically significant between groups.
Meta-analysis limitations include underpowered sample size, quantitative methods not used to identify source of heterogeneity, and lack of generalizability due to the use of studies from China.
“Mon + Flu is effective and safe for the treatment of CVA in children,” the investigators concluded. The analysis authors wrote, “Further prospective cohort studies with high quality and large samples are needed to verify the authenticity of the results.”

















